ArticleMedicine2020

Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).

Maki Ishii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.